Rockwell Medical Inc RMTI.OQ RMTI.O is expected to show a rise in quarterly revenue when it reports results on March 20 for the period ending December 31 2024
The Wixom Michigan-based company is expected to report a 7.1% increase in revenue to $23.653 million from $22.09 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on November 12 2024, for the period ended December 31, was for revenue between $23.00 million and $25.00 million.
LSEG's mean analyst estimate for Rockwell Medical Inc is for earnings of 2 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Rockwell Medical Inc is $6.50, above its last closing price of $1.77.
This summary was machine generated March 18 at 10:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。